Abstract
Photodynamic therapy (PDT) is a relatively new cytotoxic treatment, predominantly used in anti-cancer approaches, that depends on the retention of photosensitizers in tumor and their activation after light exposure. Photosensitizers are photoactive compounds such as porphyrins and chlorins that upon photoactivation, effect strongly localized oxidative damage within the target cells. The ability to confine activation of the photosensitizer by restricting illumination to the tumor allows for a certain degree of selectivity. Nevertheless, the targeted delivery of photosensitizers to defined cells is a major problem in PDT of cancer, and one area of importance is photosensitizer targeting. Alterations or increased levels in receptor expression of specific cellular type occur in the diseased tissues. Therefore, photosensitizers can be covalently attached to molecules such as peptides, leading to a receptor-mediated targeting strategy. These active-targeting approaches may be particularly useful for anti-vascular PDT. Moreover, it has been shown that the photocytotoxicity of photodynamic drugs could be enhanced by delivering high amounts of a photosensitizer into subcellular organelles such as the nucleus where nucleic acids represent target molecules sensitive to photodamage. The recent progresses in the use of active-targeting strategy with synthetic peptides and the interest of using an activetargeting strategy in PDT, which could allow efficient cellular internalization of photosensitizers, are described in this review.
Keywords: Photosensitizer, photodynamic therapy, synthetic peptides, targeted delivery, nuclear localization sequence
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Improvements in the Use of Synthetic Peptides for a Selective Photodynamic Therapy
Volume: 6 Issue: 5
Author(s): Raphael Schneider, Loraine Tirand, Celine Frochot, Regis Vanderesse, Noemie Thomas, Julien Gravier, Francois Guillemin and Muriel Barberi-Heyob
Affiliation:
Keywords: Photosensitizer, photodynamic therapy, synthetic peptides, targeted delivery, nuclear localization sequence
Abstract: Photodynamic therapy (PDT) is a relatively new cytotoxic treatment, predominantly used in anti-cancer approaches, that depends on the retention of photosensitizers in tumor and their activation after light exposure. Photosensitizers are photoactive compounds such as porphyrins and chlorins that upon photoactivation, effect strongly localized oxidative damage within the target cells. The ability to confine activation of the photosensitizer by restricting illumination to the tumor allows for a certain degree of selectivity. Nevertheless, the targeted delivery of photosensitizers to defined cells is a major problem in PDT of cancer, and one area of importance is photosensitizer targeting. Alterations or increased levels in receptor expression of specific cellular type occur in the diseased tissues. Therefore, photosensitizers can be covalently attached to molecules such as peptides, leading to a receptor-mediated targeting strategy. These active-targeting approaches may be particularly useful for anti-vascular PDT. Moreover, it has been shown that the photocytotoxicity of photodynamic drugs could be enhanced by delivering high amounts of a photosensitizer into subcellular organelles such as the nucleus where nucleic acids represent target molecules sensitive to photodamage. The recent progresses in the use of active-targeting strategy with synthetic peptides and the interest of using an activetargeting strategy in PDT, which could allow efficient cellular internalization of photosensitizers, are described in this review.
Export Options
About this article
Cite this article as:
Schneider Raphael, Tirand Loraine, Frochot Celine, Vanderesse Regis, Thomas Noemie, Gravier Julien, Guillemin Francois and Barberi-Heyob Muriel, Recent Improvements in the Use of Synthetic Peptides for a Selective Photodynamic Therapy, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (5) . https://dx.doi.org/10.2174/187152006778226503
DOI https://dx.doi.org/10.2174/187152006778226503 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery and Evaluation of Efficient Selenazoles with High Antifungal Activity Against Candida spp.
Medicinal Chemistry Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued) Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Recent Advances in Metabolites from Medicinal Plants in Cancer Prevention and Treatment
Current Immunology Reviews (Discontinued) Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Circular RNAs in Eukaryotic Cells
Current Genomics Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies
Current Pharmaceutical Design Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Current Topics in Medicinal Chemistry Synthesis and in vitro Antitumor Effect of New Vindoline Derivatives Coupled with Triphenylphosphine
Current Organic Chemistry Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Paracrine Provision of Lipids in the Immune System
Current Immunology Reviews (Discontinued) Multitasking of Neuropeptide Y through the Lens of Motifs
Recent Patents on CNS Drug Discovery (Discontinued)